Kornimate/medical-research-clean huggingface dataset:
effect of scapular stabilization excercise with pectoralis minor stretching in ballers having scapular dyskinesia

Conditions: Scapular Dyskinesis; Pectoralis Minor Syndrome

Summary: the study is randomized and single -blinded. ethical approval is taken from ethical committee of riphah international university lahore. participant selected through non probability convenience sampling technique on 26 fast bowlers which further players were randomly divided into two groups, group a (experimental group) and group b (control group), having 13 players in each group. scapular stabilization exercises along with pectoralis minor stretching were administered in group a whereas generalized shoulder exercises along with self-stretching of shoulder muscles were performed in group b.

it will be randomized controlled trial (rct) research design at al fatah sports complex and saeed ajmal cricket academy through non probability convenience sampling technique on 26 fast bowlers which further players were randomly divided into two groups, group a (experimental group) and group b (control group), having 13 players in each group. scapular stabilization exercises along with pectoralis minor stretching were administered in group a whereas generalized shoulder exercises along with self-stretching of shoulder muscles were performed in group b. assessment will be made by pocket radar, pectoralis minor index and vernier caliper. there will be 3 sessions in a week for 6 weeks. the baseline scoring will be on 1st day, follow up will be taken at 6th week. data will be analyzed during spss software version 26. after assessing normality of data by shapiro-wilk test, it will be decided either parametric or non-parametric test will be used within a group or between two groups.

Eligibility criteria:
inclusion criteria: male fast ballers * 21-30 years of age * duration of playing at least 1 to 2 years * dominant side effected exclusion criteria: * • old fracture at effected arm * any serious injury during treatment * patient with cervical spondylosis and neurological abnormalities at effected arm

Keywords: velocity strenght scapular stabilization
austrian multivessel taxus-stent registry

Conditions: Coronary Artery Disease

Summary: the aim of autax study is to investigate the frequency of macce in patients with multivessel disease and multiple taxus stent implantations in the "real world" stenting at 30 days, 6 and 12 months at 2 year follow-up. because multivessel stenting using des has been limited due to economic considerations, the secondary aim is to enhance experience in multivessel stenting with drug-eluting stents in order to improve short- and long-term outcomes of the patients with severe multiple coronary artery stenoses. the objectives of the study are: 1. to determine the frequency of macce at 30-day, 6 and 12-month and at 2 year clinical follow-up after multivessel intervention with drug-eluting stents in a prospective patient cohort.. 2. to determine the rate of in-stent restenosis, target lesion and target vessel revascularization (angiographic measures) 6 months in patients with multiple dess in multiple lesions. 3. to investigate the clinical and angiographic outcomes after implantation of multiple dess in the subgroup of patients with accompanying diseases (diabetes mellitus, renal insufficiency) with known high restenosis and late complication rate. 4. to evaluate potential cost burden in attempting a strategy of complete revascularization by multiple des in patients with multivessel disease.


Eligibility criteria:
inclusion criteria: * symptomatic coronary multivessel disease * possible percutaneous complete coronary revascularization * age \>18 year * significant coronary lesion at least in 2 vessels exclusion criteria: * acute myocardial infarction within 48 hours * contraindications to clopidogrel, aspirin, heparin and taxol * pregnancy or lack of protection against pregnancy or breast-feeding during the study * hemorrhagic diathesis * platelet count \<100.000/ml3

Keywords: coronary artery disease drug-eluting stent percutaneous coronary intervention major adverse cardiac event in-stent restenosis stent thrombosis
cone beam ct for daily image guidance - prostate cancer

Conditions: Prostatic Neoplasms

Summary: conformal dose escalated radiation therapy (crt) is standard treatment for patients with low and intermediate risk prostate cancer. crt requires accurate daily localization of the prostate prior to treatment to correct for prostate motion and set-up errors. cone beam computed tomography (ct) can accurately localize fiducial markers within the prostate. cone beam ct also provides important information on daily position of organs within the pelvis. this study aims to assess the feasibility of cone beam ct for daily localization of the prostate as well as document changes in size and location of pelvic organs during an entire course of crt.


Eligibility criteria:
inclusion criteria: * diagnosis of adenocarcinoma of the prostate * patient undergoing dose escalated conformal external beam radiation therapy * low or intermediate risk prognostic factors (psa 20 or less, gleason score \<8, clinical t category \<t3, clinical n category 0 or x, m category 0 or x * age 18 years or older * ecog performance status 0 or 1 * informed consent exclusion criteria: * inflammatory bowel disease or collagen vascular disease
proprioceptive fatigue adaptation in osteoarthritis

Conditions: Osteoarthritis of Knee; Proprioception; Isokinetic Test; Gonarthritis

Summary: this study aims to investigate the effects of fatigue induced by isokinetic exercise on passive and active joint position sense in postmenopausal women diagnosed with knee osteoarthritis (gonarthrosis). a healthy control group matched for age and sex will also be included for comparative analysis. participants will undergo proprioceptive assessments before and after an isokinetic fatigue protocol. we hypothesize that (1) fatigue will impair both passive and active joint position sense in patients with gonarthrosis, (2) active joint position sense will be more affected than passive sense, and (3) the deterioration in proprioception will be greater in the gonarthrosis group compared to healthy controls.

osteoarthritis, particularly knee osteoarthritis (gonarthrosis), is a progressive musculoskeletal disease that severely affects lower extremity functions. proprioceptive impairments in these patients can lead to altered motor control, reduced movement accuracy, and increased risk of falls. fatigue may exacerbate these impairments by affecting sensory feedback from muscle spindles and joint receptors, which is critical for joint stability and motor control. in postmenopausal women, hormonal changes further compound muscle weakness and joint instability, highlighting the clinical importance of understanding proprioceptive changes following fatigue. this experimental study will involve two groups: postmenopausal women with gonarthrosis and age-matched healthy controls. participants will undergo an isokinetic fatigue protocol followed by assessments of passive and active joint position sense being more vulnerable. understanding these changes will contribute to developing rehabilitation strategies focusing on proprioception and fatigue management. we expect that isokinetic fatigue will impair proprioception, with active joint position

Eligibility criteria:
inclusion criteria: * female, aged 50-65 * postmenopausal * grade 2-3 knee osteoarthritis (kellgren-lawrence scale) for oa group * no lower extremity surgery in the last 6 months * no neuromuscular or orthopedic condition affecting the lower extremities exclusion criteria: * severe balance disorders or vestibular disease * bilateral knee prosthesis or severe osteoporosis * lower extremity musculoskeletal injury in the last 6 months

Keywords: osteoarthritis of knee propripception isokinetic test gonarthritis
dose ranging study of solabegron versus placebo in female patients with overactive bladder symptoms

Conditions: Overactive Bladder

Summary: this study will test the effectiveness and safety of two doses of solabegron against placebo in reducing the symptoms of overactive bladder.


Eligibility criteria:
inclusion criteria: * overactive bladder with symptoms of urgency with urge incontinence and frequency which may be associated with nocturia but without bladder pain. * body mass index in the range of = 19 kg/m2 to \<35 kg/m2. exclusion criteria: * pregnant * of childbearing potential or willing to use specific barrier methods outlined in the protocol. * grade iii/iv pelvic organ prolapse with or without cystocele. * history of interstitial cystitis or bladder related pain. * stress incontinence or mixed incontinence where stress incontinence is the predominant component based on prior history. * history of pelvic prolapse repair (cystocele or rectocele) or urethral diverticulectomy within six months of screening. * urinary incontinence due to causes other then detrusor over activity (e.g., overflow incontinence). * nocturnal enuresis only. * urinary retention, or other evidence of poor detrusor function. * current or history of urinary tract infection. * diabetes insipidus. * history of myocardial infarction, unstable angina, or congestive heart failure. * chronic severe constipation. * history of prior anti-incontinence surgery. * history of radiation cystitis or a history of pelvic irradiation. * electrostimulation, biofeedback, or bladder training therapy (behavioral therapy) during the previous month prior to screening, or the intention to initiate such therapies during the study. pessaries and implants are also excluded. * received any investigational product within 30 days of enrollment into the study.

Keywords: overactive bladder
a study of mci-196 in chronic kidney disease subjects on dialysis with hyperphosphatemia and dyslipidaemia

Conditions: Chronic Kidney Disease; Dialysis; Hyperphosphatemia; Dyslipidemia

Summary: this is a phase iii multi-centre study in two periods: the first period is a phosphate binder and lipid lowering drugs washout for 8 weeks, the second period is a double-blind, randomised, parallel group, fixed dose, for 12 weeks.


Eligibility criteria:
inclusion criteria: * male or female, 18 years of age or over * clinically stable haemodialysis or peritoneal dialysis * stable phosphate control * on a stabilised phosphorus diet * female and of child-bearing potential have a negative serum pregnancy test * male subjects must agree to use appropriate contraception exclusion criteria: * current clinically significant medical comorbidities, which may substantially compromise subject safety, or expose them to undue risk, or interfere significantly with study procedures and which, in the opinion of the investigator, makes the subject unsuitable for inclusion in the study. * a a serum albumin level\<30.0g/l * a pth level \>1000pg/ml * a body mass index (bmi)\ 40.0kg/㎡ * a serum ldl-c level \>4.94mmol/l(190mg/dl) * a serum triglycerides level \>6.76mmol/l (600mg/dl) * a history of significant gastrointestinal motility problems * a positive test for hiv 1 and 2 antibodies * a history of substance or alcohol abuse within the last year * seizure disorders * a history of drug or other allergy * a temporary catheter as a vascular access * participated in a clinical study with any experimental medication in the last 30 days or an experimental biological product within the last 90 days prior to signing of informed consent

Keywords: chronic kidney disease dialysis hyperphosphatemia dyslipidemia phosphate binder
pharmacogenomics studies of antidepressants

Conditions: Major Depressive Disorder; Antidepressive Agents; Pharmacogenetics; Venlafaxine; Fluoxetine

Summary: the purpose of this study is to establish the clinical effectiveness of antidepressants by pharmacogenomic approach, and to determine the levels of inflammatory factors between the baseline and the end point of the study in taiwanese major depressive disorder (mdd) patients.


Eligibility criteria:
inclusion criteria: * age: 16-65 years old * signed informed consent by patient or legal representative * hamilton rating scale for depression (hdrs) scores ≥ 16 * a diagnosis of mdd according to dsm-iv criteria made by a specialist in psychiatry exclusion criteria: * monoamine oxidase inhibitor or antidepressant treatment within two weeks prior to entering the study * a dsm-iv diagnosis of substance abuse within the past three months * an organic mental disease, mental retardation or dementia * a serious surgical condition or physical illness * patients who were pregnant or breastfeeding

Keywords: major depressive disorder antidepressants pharmacogenetics venlafaxine fluoxetine
intervention to improve care at life's end

Conditions: Death; Pain; Dyspnea

Summary: the beacon trial (best practices for end-of-life care for our nations' veterans) was a six-site implementation study to evaluate a multi-component, education-based intervention to improve the quality of end-of-life care provided in va medical centers.

the beacon trial (best practices for end-of-life care for our nations' veterans) was a six-site, real-world implementation trial of a multi-component, education-based intervention to improve the quality of end-of-life care conducted in va medical centers (vamcs). the primary aim was to evaluate the effectiveness of a multi-component intervention for improving processes of care provided in the last days of life in vamcs. the second aim was to conduct after-death interviews with next-of-kin and qualitative analysis of their perceptions of the care provided to the veteran and family. the multi-component intervention targeted vamc inpatient providers, including physician, nursing, and ancillary staff. it consisted of preparatory site visits, a staff training program, a newly developed comfort care order set decision support tool built into the cprs, and follow-up consultation. the intervention team travelled to each site to conduct two weeks of comprehensive in-service training. staff were trained to identify actively-dying patients and implement a set of best practices of traditionally home-based hospice care for dying patients. the team provided assistance with policies, procedures, and skill training needed to implement comfort care interventions. introduction of the intervention at each vamc was staggered across time at six-month intervals using a multiple-baseline, stepped wedge design. data on processes of end-of-life care (last 7 days) were abstracted from the cprs medical records of all veterans who died before, during, and after the intervention (january 2005-february 2011). a priori, five processes of care were identified as primary endpoints to indicate quality of end-of-life care: 1) presence of an order for opioid pain medication at time of death; 2) a do-not-resuscitate (dnr) order in place at time of death; 3) location of death; 4) presence of enteral feeding tube or intravenous line at time of death; and 5) physical restraints in place at or near time of death. in addition, in-depth, face-to-face interviews were conducted with 78 bereaved next-of-kin.

Eligibility criteria:
inclusion criteria: * aim 1: not applicable. patients were deceased. * aim 2: after-death interviews with next of kin: must be willing and able to participate in after-death interview at local va medical center. exclusion criteria: * n/a

Keywords: palliative care terminal care hospice care patient care planning nursing care plans quality of health care inpatients professional education resuscitation orders pastoral care
morphological markers of gastroesophageal reflux disease (gerd)

Conditions: Eosinophilic Esophagitis; Gastroesophageal Reflux Disease

Summary: the purpose of this project is to learn more about a new and promising way to diagnose acid reflux disease using a very high-powered microscope. this special microscope provides much finer detail than typical microscopes previously used for diagnosing reflux, and may help doctors to better identify children with acid reflux.

this will be a prospective case control study. children between the ages of 8 and 18 with suspected gastroesophageal reflux disease (gerd) or eosinophilic esophagitis (eoe) based on symptom criteria and who have been scheduled for esophagogastroduodenoscopy (egd) by their primary gastroenterologist will be recruited. children who do not have any history of esophageal disease or esophageal symptoms and are scheduled for egd for other clinical indications (e.g. rule out celiac disease) by their primary gastroenterologist will be recruited and act as controls. control subjects will also be given the opportunity to undergo esophageal mii-ph monitoring as part of their medical evaluation, but will not be excluded from analysis should they opt out of this part of the study. for all subjects, in addition to endoscopic evaluation, biopsies of the distal esophagus will be obtained for routine light microscopy (standard histology sample) as well as transmission electron microscopy (tem) analysis to determine the presence and magnitude of dilated intercellular spaces (dis), and immunoblotting for e-cadherin cleavage

Eligibility criteria:
inclusion criteria for gerd or eoe subjects: * children between the ages of 8-18 years * suspected diagnosis of gerd or eoe based on symptom criteria * able to tolerate upper endoscopy examination with biopsies inclusion criteria for control subjects: * children between the ages of 8-18 * scheduled for egd for clinical indications * no history of esophageal disease of esophageal symptoms * able to tolerate upper endoscopy examination with biopsies exclusion criteria for gerd or eoe subjects: * history of barrett's esophagus * previous esophageal or gastric surgery * history of congenital defect/malformation of the esophagus * diagnosis of crohn disease exclusion criteria for control subjects: * symptoms of gerd or eoe (including heartburn, regurgitation, difficulty swallowing, painful swallowing).

Keywords: eosinophil reflux esophagus food allergy trouble swallowing pediatrics healthy volunteers
effect of deferasirox on endocrine complications in subjects with transfusion dependent thalassemia

Conditions: Thalassemia (Transfusion Delendent)

Summary: the centaurus trial is a prospective clinical study designed to address systematically some of the relevant endocrine complications in an iron overloaded thalassemic population, primary objective being the assessment of the effect of deferasirox therapy on glucose metabolism/homeostasis. other endocrine parameters complementary or supportive to the primary objective will be assessed and analyzed during this study. a number of lab parameters related to other axes of the endocrine system will be collected and analyzed.


Eligibility criteria:
inclusion criteria: 1. beta thalassemia major and severe intermedia patients transfusion dependent and with transfusional iron overload 2. patients with diagnosis of impaired fasting glucose or impaired glucose tolerance 4.patients naïve to deferasirox or patients who already receive deferasirox at sub-optimal doses 5.cardiac mri t2\* \>10 msec; 7.normal cardiac function (lvef \> 56%); exclusion criteria: 1. non transfusional hemosiderosis; 2. patients with diabetes mellitus (genetic or secondary) or history of diabetes mellitus in 1st degree relatives; 4.patients who received organ transplant; 5.patients with galactose intolerance, severe lactase deficiency or glucose-galactose malabsorption; 6.patients unable to tolerate (or who have unacceptable toxicities to) prior treatment with deferasirox; 7.history of hypersensitivity to the study drug or any of its excipients; 8. renal impairment 10. liver impairment; 11.patients with active chronic hepatitis b infection, active hepatitis c infection; other protocol-defined inclusion/exclusion criteria may apply" at the end

Keywords: endocrine complications transfusion dependent thalassemia
bendamustine in patients with refractory or relapsed t-cell lymphoma

Conditions: T-cell Lymphoma

Summary: a phase ii clinical study to determine the efficacy of single agent bendamustine for t cell lymphoma "bently".

the primary objective of this study is to define the activity of bendamustine for the treatment of t cells lymphomas. the activity of bendamustine is determined by the response rate (rr) to the treatment within 22 days after intravenous infusion which enables to get a confidence interval of 95 % for the probability of an overall response rate (orr).

Eligibility criteria:
inclusion criteria: * patients aged more than 18 years. * refractory or relapsed peripheral t-cell nhl (ptcl) * cutaneous t cell lymphoma (ctcl) in relapse or refractory to topical therapy * ecog score less than 2 * no major organ dysfunction unrelated to lymphoma. exclusion criteria: * pregnant or breast feeding women * ecog score \> 2 * estimate survival time \< 3 months * active infection or severe organ dysfunction or psychiatric condition that unable patients to receive chemotherapy * creatinine clearance \< 10 ml/min or severe hepatic dysfunction not related to lymphoma. * previous chemotherapy/immunotherapy within 3 weeks before study entry * known seropositive for or active viral infection hiv, ebv, hcv * cns lymphoma * t-cell leukemia lymphoma associated with htlv1 * sezary syndrome

Keywords: bendamustine refractory or relapsed t-cell lymphoma.
detection of subclinical cerebral suffering related to hypertension using multimodal mri

Conditions: Hypertension

Summary: investigators propose here to study the brain consequences of hypertension in patients without cognitive complaints and neurological signs. the evaluation of brain suffering requires considering various possible brain damage. the team developed a multimodal mri approach capable of detecting and quantifying numerous indices (e.g. morphometric, microstructural) to evaluate possible brain suffering. this project aims to identify individually signs of cerebral suffering in hypertensive patients compared to a population of normotensive volunteers, using advanced multiparametric mri methods.

hypertension is a risk factor for many brain pathologies, such as ischemic and hemorrhagic neurodegenerative diseases or stroke. the literature seems to agree on the relationship between hypertension and brain damage, and on the benefit of the management of hypertension to prevent certain neurological pathologies. however, to our knowledge, no single study has shown signs of subclinical brain damage in patients with hypertension. at present, no brain mri is recommended in these patients. in the present study, hypertensive and normotensive patients will undergo a neurological exam, a neuropsychological exam, a biological exam and a mri exam to individually identify signs of cerebral suffering.

Eligibility criteria:
inclusion criteria: * male and female 35 to 50 y.o.;for patients: diagnosed hta within 5 years, treated or confirmed by ambulatory blood pressure measure; * for normotensive participants:absence of hta confirmed by ambulatory blood pressure measure exclusion criteria: * known neurological history, stroke, symptomatic headache, long-term use of neuroleptic, tricyclic, maoi, anti-serotonergic antidepressant medications, diabetes mellitus, treated dyslipidemia, body mass index greater than 30 kg / m, participants who smoked or smoked more than 10 packs-year, mri contraindication ; * for hta patients only: renal artery dysplasia responsible for hypertension, clinical cushing syndrome.

Keywords: mri, hypertension